Therefore, if there is a deficiency in vitamin B 12, macrocytic anemia may occur
Z.ShamsiA
Interventions: VK2735 Primary Outcome Measure: Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment Time Frame: 78 weeks Study Details Source VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) Sponsor: Viking Therapeutics Goal: This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight
Conclusions In summary, semaglutide PK was shown to be predictable across clinical pharmacology and phase 3 trials, with limited interindividual variability that was primarily influenced by body weight
By comparison, several competitors offer true money-back guarantees